Antibiotic Resistance in Urine Culture Isolates from Hospitalized Children Under Five Years with Urinary Tract Infection: A Comparison of the 2019-2020 and 2024-2025 Periods.
- 1Department of Pediatrics, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34890, Türkiye.
- 2Faculty of Health Sciences, Sinop University, Sinop 57000, Türkiye.
Abstract
Background/Objectives: We evaluated changes in antibiotic resistance among urine culture isolates from children under five years hospitalized with urinary tract infection (UTI) at a single center in 2019-2020 and 2024-2025. Methods: This retrospective, repeated cross-sectional study included 498 children and analyzed 359 isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus spp. As second-line agents were tested selectively, primary outcomes (defined post hoc) were resistance to a core panel of agents tested in at least 90% of isolates and core-panel multidrug resistance (MDR) in Enterobacterales; other comparisons were exploratory. Fisher's exact test, Benjamini-Hochberg correction, and adjusted Firth regression were used. Results: Second-line agents were tested mainly in cefuroxime-resistant isolates (95% vs. 7% for ceftazidime in E. coli), biasing resistance estimates. In the core panel, no difference was significant in E. coli, and the decrease in cefuroxime resistance in K. pneumoniae did not survive correction. Core-panel MDR was lower in 2024-2025 (51.9% vs. 38.7%; p = 0.019; adjusted OR 0.56, 95% CI 0.35-0.88); full-category MDR was not (68.4% vs. 58.3%; p = 0.067). Conclusions: Differences may reflect testing practices and case mix rather than true changes in resistance. Findings apply only to hospitalized children under five years at this center and require confirmation.
Related
- In vitro experimental evaluation of the antibacterial, antibiotic-synergistic, and anti-motility effects of eugenol against clinical Pseudomonas aeruginosa isolates from hospitalized animals
- Risk Factors for Colonization With Antibiotic-Resistant Bacteria Among Hospitalized Patients in Bangladesh: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study
- Prevalence of Antibiotic Resistance Among Common Clinical Bacterial Isolates From Kalar City, Iraq
- Antibiotic resistance patterns and associated genetic determinants among clinical isolates of Pseudomonas aeruginosa from a tertiary hospital in southern Iraq
- An Exploratory Study on the Antibiotic Potentiation Activity of Riboflavin Against Biofilm‐Forming Multidrug‐Resistant Salmonella and Shigella Clinical Isolates
BibTeX
@article{gun2026antibiotic,
title = {{Antibiotic Resistance in Urine Culture Isolates from Hospitalized Children Under Five Years with Urinary Tract Infection: A Comparison of the 2019-2020 and 2024-2025 Periods.}},
author = {Elife Çapan Gün and Şeyma Şimşirgil Kara and Yasemin Akın},
journal = {Antibiotics (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antibiotics15101031},
url = {https://europepmc.org/article/MED/42938772},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antibiotic Resistance in Urine Culture Isolates from Hospitalized Children Under Five Years with Urinary Tract Infection: A Comparison of the 2019-2020 and 2024-2025 Periods.
AU - Elife Çapan Gün
AU - Şeyma Şimşirgil Kara
AU - Yasemin Akın
PY - 2026
DA - 2026/10/16
JO - Antibiotics (Basel, Switzerland)
DO - 10.3390/antibiotics15101031
UR - https://europepmc.org/article/MED/42938772
AB - Background/Objectives: We evaluated changes in antibiotic resistance among urine culture isolates from children under five years hospitalized with urinary tract infection (UTI) at a single center in 2019-2020 and 2024-2025. Methods: This retrospective, repeated cross-sectional study included 498 children and analyzed 359 isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus spp. As second-line agents were tested selectively, primary outcomes (defined post hoc) were resistance to a core panel of agents tested in at least 90% of isolates and core-panel multidrug resistance (MDR) in Enterobacterales; other comparisons were exploratory. Fisher's exact test, Benjamini-Hochberg correction, and adjusted Firth regression were used. Results: Second-line agents were tested mainly in cefuroxime-resistant isolates (95% vs. 7% for ceftazidime in E. coli), biasing resistance estimates. In the core panel, no difference was significant in E. coli, and the decrease in cefuroxime resistance in K. pneumoniae did not survive correction. Core-panel MDR was lower in 2024-2025 (51.9% vs. 38.7%; p = 0.019; adjusted OR 0.56, 95% CI 0.35-0.88); full-category MDR was not (68.4% vs. 58.3%; p = 0.067). Conclusions: Differences may reflect testing practices and case mix rather than true changes in resistance. Findings apply only to hospitalized children under five years at this center and require confirmation.
SN - 2079-6382
ER -